Light Mode
$11.80 ↓ -0.18 (-1.50%) Trading Down from the previous close of $11.98, $0.69 below the day’s high of $12.49
-1.54 (-11.36%) / 6M
Momentum, market sentiment, and recent alerts
KRRO reads very good: price sits above one of the two key moving averages, the 12-month move is -67.9%.
Earnings, valuation, and balance sheet
Company profile and competitor comparison
Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.
No peer group available for this symbol.
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.